Form 8-K Lipocine Inc. For: Oct 07

Go back to Form 8-K Lipocine Inc. For: Oct 07

Health Canada approves Tlando oral testosterone therapy from Lipocine

October 7, 2026 6:13 AM EDT

Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy (TRT) in adult males with hypogonadism, according to a statement from Lipocine Inc. (NASDAQ: LPCN).

The approval was obtained through Verity Pharmaceuticals Inc., Lipocine's licensing partner, which holds exclusive commercial... More